{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T01:55:39Z","timestamp":1790474139700,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,2]],"date-time":"2015-12-02T00:00:00Z","timestamp":1449014400000},"content-version":"vor","delay-in-days":914,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1097\/jto.0b013e31828c2b26","type":"journal-article","created":{"date-parts":[[2013,4,9]],"date-time":"2013-04-09T13:23:52Z","timestamp":1365513832000},"page":"783-787","source":"Crossref","is-referenced-by-count":68,"title":["Phase 2 Study of Sorafenib in Malignant Mesothelioma Previously Treated with Platinum-Containing Chemotherapy"],"prefix":"10.1016","volume":"8","author":[{"given":"Sophie","family":"Papa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Popat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riyaz","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Toby","family":"Prevost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Lal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blair","family":"McLennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Cane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loic","family":"Lang-Lazdunski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaid","family":"Viney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel T.","family":"Dunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Barrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Landau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Spicer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1097\/JTO.0b013e31828c2b26_bib1","first-page":"260","article-title":"Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province","volume":"17","author":"Wagner","year":"1960","journal-title":"Br J Ind Med"},{"key":"10.1097\/JTO.0b013e31828c2b26_bib2","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/sj.bjc.6602307","article-title":"The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050","volume":"92","author":"Hodgson","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1097\/JTO.0b013e31828c2b26_bib3","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e31828c2b26_bib4","doi-asserted-by":"crossref","first-page":"6881","DOI":"10.1200\/JCO.20005.14.589","volume":"23","author":"van Meerbeeck","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e31828c2b26_bib5","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000029460","article-title":"Co-expression of vascular endothelial growth factor and its receptor flt-1 in malignant pleural mesothelioma","volume":"67","author":"K\u00f6nig","year":"2000","journal-title":"Respiration"},{"key":"10.1097\/JTO.0b013e31828c2b26_bib6","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<72::AID-PATH401>3.0.CO;2-0","article-title":"Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF beta expression","volume":"189","author":"Kumar-Singh","year":"1999","journal-title":"J Pathol"},{"key":"10.1097\/JTO.0b013e31828c2b26_bib7","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/sj.bjc.6690650","article-title":"VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours","volume":"81","author":"Ohta","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1097\/JTO.0b013e31828c2b26_bib8","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/path.824","article-title":"Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma","volume":"193","author":"Strizzi","year":"2001","journal-title":"J Pathol"},{"key":"10.1097\/JTO.0b013e31828c2b26_bib9","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/ijc.10996","article-title":"Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops","volume":"104","author":"Masood","year":"2003","journal-title":"Int J Cancer"},{"key":"10.1097\/JTO.0b013e31828c2b26_bib10","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1378\/chest.128.5.3382","article-title":"Prognostic significance of vascular endothelial growth factor, tumor necrosis, and mitotic activity index in malignant pleural mesothelioma","volume":"128","author":"Demirag","year":"2005","journal-title":"Chest"},{"key":"10.1097\/JTO.0b013e31828c2b26_bib11","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1200\/JCO.2011.41.5869","article-title":"Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine\/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma","volume":"30","author":"Kindler","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e31828c2b26_bib12","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.2174\/1381612023393125","article-title":"Design and discovery of small molecules targeting raf-1 kinase","volume":"8","author":"Lowinger","year":"2002","journal-title":"Curr Pharm Des"},{"key":"10.1097\/JTO.0b013e31828c2b26_bib13","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Cancer Res"},{"key":"10.1097\/JTO.0b013e31828c2b26_bib14","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s00280-006-0393-4","article-title":"Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models","volume":"59","author":"Chang","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1097\/JTO.0b013e31828c2b26_bib15","doi-asserted-by":"crossref","first-page":"11851","DOI":"10.1158\/0008-5472.CAN-06-1377","article-title":"Sorafenib blocks the RAF\/MEK\/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC\/PRF\/5","volume":"66","author":"Liu","year":"2006","journal-title":"Cancer Res"},{"key":"10.1097\/JTO.0b013e31828c2b26_bib16","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1158\/0008-5472.CAN-05-0808","article-title":"The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells","volume":"66","author":"Panka","year":"2006","journal-title":"Cancer Res"},{"key":"10.1097\/JTO.0b013e31828c2b26_bib17","doi-asserted-by":"crossref","first-page":"35217","DOI":"10.1074\/jbc.M506551200","article-title":"Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation","volume":"280","author":"Rahmani","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1097\/JTO.0b013e31828c2b26_bib18","doi-asserted-by":"crossref","first-page":"6861","DOI":"10.1038\/sj.onc.1208841","article-title":"The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006","volume":"24","author":"Yu","year":"2005","journal-title":"Oncogene"},{"key":"10.1097\/JTO.0b013e31828c2b26_bib19","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1200\/JCO.2009.27.7988","article-title":"Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203","volume":"28","author":"Sun","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e31828c2b26_bib20","doi-asserted-by":"crossref","first-page":"4714","DOI":"10.1200\/JCO.2008.16.3279","article-title":"Phase II trial of sorafenib in advanced thyroid cancer","volume":"26","author":"Gupta-Abramson","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e31828c2b26_bib21","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1158\/1078-0432.CCR-07-1355","article-title":"A phase II clinical trial of sorafenib in androgen-independent prostate cancer","volume":"14","author":"Dahut","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e31828c2b26_bib22","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1200\/JCO.2007.15.5242","article-title":"Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336","volume":"27","author":"Moreno-Aspitia","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e31828c2b26_bib23","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1158\/1078-0432.CCR-10-2331","article-title":"Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib","volume":"17","author":"Kelly","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e31828c2b26_bib24","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1200\/JCO.2009.22.0541","article-title":"Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer","volume":"27","author":"Blumenschein","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e31828c2b26_bib25","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1097\/JTO.0b013e31828c2b26_bib26","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1097\/JTO.0b013e31828c2b26_bib27","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdh059","article-title":"Modified RECIST criteria for assessment of response in malignant pleural mesothelioma","volume":"15","author":"Byrne","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1097\/JTO.0b013e31828c2b26_bib28","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1200\/JCO.2005.05.1359","article-title":"Progression-free survival rate as primary end point for phase II cancer clinical trials: application to mesothelioma\u2013The EORTC Lung Cancer Group","volume":"24","author":"Francart","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e31828c2b26_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"key":"10.1097\/JTO.0b013e31828c2b26_bib30","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1200\/JCO.2011.40.6942","article-title":"The challenge of choosing appropriate end points in single-arm phase II studies of rare diseases","volume":"30","author":"Sleijfer","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e31828c2b26_bib31","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1097\/JTO.0b013e3181ec18db","article-title":"A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307","volume":"5","author":"Dubey","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1097\/JTO.0b013e31828c2b26_bib32","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1097\/JTO.0b013e318229586e","article-title":"Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509","volume":"6","author":"Garland","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1097\/JTO.0b013e31828c2b26_bib33","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.lungcan.2011.11.014","article-title":"Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107)","volume":"76","author":"Jahan","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1097\/JTO.0b013e31828c2b26_bib34","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1097\/JTO.0b013e31825f22ee","article-title":"A phase II study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesothelioma","volume":"7","author":"Nowak","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1097\/JTO.0b013e31828c2b26_bib35","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1097\/JTO.0b013e3182333df5","article-title":"Brief report: a phase II study of sunitinib in malignant pleural mesothelioma. the NCIC Clinical Trials Group","volume":"6","author":"Laurie","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1097\/JTO.0b013e31828c2b26_bib36","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1200\/JCO.2010.29.3787","article-title":"Bar the windows but open the door to randomization","volume":"28","author":"Ratain","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e31828c2b26_bib37","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(08)60727-8","article-title":"Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomized trial","volume":"371","author":"Muers","year":"2008","journal-title":"Lancet"},{"key":"10.1097\/JTO.0b013e31828c2b26_bib38","doi-asserted-by":"crossref","first-page":"5094","DOI":"10.1200\/JCO.2005.02.520","article-title":"Evaluation of randomized discontinuation design","volume":"23","author":"Freidlin","year":"2005","journal-title":"J Clin Oncol"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415328550?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415328550?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,12]],"date-time":"2019-07-12T06:05:22Z","timestamp":1562911522000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086415328550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["S1556086415328550"],"URL":"https:\/\/doi.org\/10.1097\/jto.0b013e31828c2b26","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]}}}